Shikonin/Galunisertib Dual-Drug Core–Shell Coaxial Gel/PCL Nanofibrous Membrane for Radiation-Induced Skin Injury
Abstract
Purpose
To develop an acetylshikonin/galunisertib dual-drug core–shell Gel/PCL nanofibrous membrane for radiation-induced skin injury.
Methods
A coaxial electrospinning strategy was used to fabricate the dual-drug membrane (acetylshikonin/α-tocopherol in the shell and galunisertib in the core) with corresponding controls. SEM/EDS, FTIR and XRD, together with vapor transmission, water uptake and in-vitro release tests, were performed. In vitro studies included HUVEC cytocompatibility and tube formation, RAW264.7 inflammation modulation in an LPS model, and planned antioxidant, anti-fibrotic and ECM synthesis assays. In vivo efficacy is being evaluated in an mouse radiation-induced skin injury model.
Results
The dual-drug GP-SG membrane exhibited the most compact fibrous network with the smallest pores and the highest crystallinity. Vapor permeability was maintained, and water uptake remained within 200–500%. In LPS-polarized RAW264.7 cells, GP-SG decreased iNOS，TNF-α and IL-1β while increasing IL-1β，IL-10 and CD206.
Conclusion
The core-shell structure fiber membrane achieves synergistic stability and barrier function, and dual drug delivery enhances anti-inflammatory, antibacterial, and antioxidant regulation, providing a new strategy for repairing radiation-induced skin damage.